Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome since obesity and insulin resistance are the main pathogenic contributors for both conditions. NAFLD carries increased risk of atherosclerosis and cardiovascular diseases. There is an urgent need to...

Descripción completa

Detalles Bibliográficos
Autores principales: Janczyk, Wojciech, Socha, Piotr, Lebensztejn, Dariusz, Wierzbicka, Aldona, Mazur, Artur, Neuhoff-Murawska, Joanna, Matusik, Pawel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672084/
https://www.ncbi.nlm.nih.gov/pubmed/23702094
http://dx.doi.org/10.1186/1471-2431-13-85

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672084/
https://www.ncbi.nlm.nih.gov/pubmed/23702094
http://dx.doi.org/10.1186/1471-2431-13-85

Ejemplares similares